REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Whole Live Micro-organism, Cell, Or Virus Containing > Genetically Modified Micro-organism, Cell, Or Virus (e.g., Transformed, Fused, Hybrid, Etc.) Genetically Modified Micro-organism, Cell, Or Virus (e.g., Transformed, Fused, Hybrid, Etc.)Genetically Modified Micro-organism, Cell, Or Virus (e.g., Transformed, Fused, Hybrid, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070190032 - Use of local immune suppression to enhance oncolytic viral therapy Provided herein are methods for treating or ameliorating a solid tumor in a subject comprising administering oncolytic viruses and immunosuppressive agents at or near the site of the tumor. ... 08/16/07 - 20070190031 - Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to hiv The invention provides a DNA plasmid comprising: (a) a first transcriptional unit comprising a nucleotide sequence that encodes a first polypeptide operably linked to regulatory elements including a first promoter and a first polyadenylation signal; (b) a second transcriptional unit comprising a nucleotide sequence that encodes a second polypeptide operably ... 08/16/07 - 20070190030 - Method of treating arthritis using lentiviral vectors in gene therapy Novel methods for treating and preventing arthritis, such as rheumatoid arthritis, are disclosed which employ lentiviral gene delivery vectors, including HIV-based lentiviral vectors, to deliver a therapeutic gene to a subject. Lentiviral-based vectors treat arthritis by promoting high-level expression of the transferred therapeutic gene in the target tissue of the ... 08/16/07 - 20070190029 - Listeria-induced immunorecruitment and activation, and methods of use thereof Provided are reagents and methods for administering an attenuated bacterium for use in treating a cancerous or infectious condition. Reagents and methods for administering an attenuated bacterium for use in inducing an immune response against a tumor, cancer cell, or infective agent are further provided. Also provided are methods of ... 08/16/07 - 20070190028 - Method and apparatus for heat or electromagnetic control of gene expression A gene regulatory system controls biomarker, gene therapy or endogenous gene expression by emitting one or more forms of energy that regulate gene expression. The system may include a sensor to sense a signal indicative of a need for therapy. The regulation of gene expression is controlled based on the ... 08/16/07 - 20070190027 - Targeting of herpes simplex virus to specific receptors The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a ... 08/09/07 - 20070184028 - Conditional gene vectors regulated in cis The present invention is directed to a conditional gene vector system and to a host cell, which has been transfected with such a vector system. The present invention is further directed to a combined preparation comprising the vector system of the invention and an interfering agent. Furthermore, a pharmaceutical composition ... 08/09/07 - 20070184027 - Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or ... 08/09/07 - 20070184026 - Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts The present invention relates to methods, agents and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts. The invention thus provides a method, comprising contacting a compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No: 194-309; and measuring ... 08/09/07 - 20070184025 - Chimaeric vector system This invention relates to a process for producing a Simian Immunodeficiency Virus (SIV) encoding a heterologous gene, which process comprises infecting a host cell with a first vector which is capable of producing SIV capsid and a second vector comprising a Human Immunodeficiency Virus type 2 (HIV-2) packaging signal sufficient ... 08/02/07 - 20070178069 - Herpes simplex virus vector The invention provides a herpes simplex virus vector comprising deletions in ICP4, ICP27, and UL55. ... 08/02/07 - 20070178068 - Compositions and methods for regulating complement system The disclosure provided herein provides for methods and compositions for modulating the human complement pathway by reducing the expression or production of one or more complement pathway protein and uses for such methods for treating diseases including ocular disease and macular degeneration related disease. The invention also includes active agents ... 08/02/07 - 20070178067 - System and method for cytological analysis by raman spectroscopic imaging A method and system of differentially manipulating cells where the cells, suspended in a fluid, are irradiated with substantially monochromatic light. A Raman data set is obtained from the irradiated cells and where the data set is characteristic of a disease status. The data set is assessed to identify diseased ... 08/02/07 - 20070178066 - Pathotropic targeted gene delivery system for cancer and other disorders Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as ... 08/02/07 - 20070178065 - Neutralizing factors as vaccine adjuvants The present invention is a vaccine adjuvant composed of a vaccinia virus vector that encodes a polypeptides capable of neutralizing immune suppressive factors thereby enhancing or stimulating an immune response to a vaccine. ... 08/02/07 - 20070178064 - Antisense iap nucleobase oligomers and uses thereof The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis and treat proliferative diseases. ... 07/26/07 - 20070172462 - Sirna-mediated gene silencing of synuclein The present invention is directed to small interfering RNAs that down regulate expression of a synuclein gene and methods of using the small interfering RNAs. ... 07/26/07 - 20070172461 - Polyepitope vaccines The present invention relates to a recombinant polyepitope cytotoxic T lymphocyte vaccine. The vaccine comprises at least one recombinant protein including a plurality of cytotoxic T lymphocyte epitopes from one or more pathogens, wherein the at least one recombinant protein is substantially free of sequences naturally found to flank the ... 07/26/07 - 20070172460 - Random peptide library displayed on aav vectors Described is a method of producing a repertoire of random peptides on the surface of AAV particles wherein said random peptides are expressed as a fusion with an AAV capsid protein of an AAV particle which displays at its surface said random polypeptides. Also described is a peptide library obtainable ... 07/19/07 - 20070166286 - Self-rearranging dna vectors Disclosed are replicatable viral DNA vectors encoding a site-specific DNA-altering enzyme and a DNA target recognized by the enzyme, the enzyme selectively converting, in a cell expressing the enzyme, the DNA vector to a rearranged form. The invention further relates to methods for assembling recombinant adenoviral DNAs. These methods include ... 07/19/07 - 20070166285 - Systems and methods related to degradation of uremic toxins The present invention generally relates to the treatment of uremic toxins in vivo using uremic toxin-treating enzymes, and/or cells capable of producing uremic toxin-treating enzymes or otherwise reacting with uremic toxins. Non-limiting examples of cases where the treatment of uremic toxins is desired include renal disease or dysfunction, gout, subjects ... 07/19/07 - 20070166284 - Therapeutic regimen for treating cancer The invention provides a method for treating cancer in a human comprising administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-α operably linked to a promoter, wherein the dose comprises about ... 07/19/07 - 20070166283 - Compositions and methods for the treatment of hemophilia a Improved materials and methods for the treatment of Hemophilia A are provided. ... 07/12/07 - 20070160581 - Production of ssdna in vivo Methods and compositions comprising a DNA expression cassette for producing ss-cDNA inside a host cell (in vivo). The expression system optionally contains a reverse transcriptase/RNAse H coding gene, and a restriction endonuclease gene. The cassette carries cloning sites in two distinct locations for cloning and expressing a sequence of interest. ... 07/05/07 - 20070154458 - Combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector A composition of matter comprising a vaccinia virus expression vector with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype. ... 07/05/07 - 20070154457 - Use of eif-5a to kill multiple myeloma cells The present invention relates to eucaryotic initiation factor 5A and the use of polynucleotides encoding the same to inhibit cancer cell growth and inhibit metastases. In a preferred embodiment, eIF-5A1 is used to kill multiple myeloma cells. ... 07/05/07 - 20070154456 - Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression Disclosed are genetic expression cassettes, and vector comprising them useful for the delivery of nucleic acid segments encoding selected therapeutic constructs (including for example, peptides, polypeptides, ribozymes, and catalytic RN molecules), to selected cells and tissues of vertebrate animals. The disclosed genetic constructs are useful in the development of gene ... 07/05/07 - 20070154455 - Monoparamunity inducers based on attenuated rabbit myxoma viruses The invention relates to monoparamunity inducers that are based on paramunizing viruses or viral components of a myxoma virus strain of diseased rabbits that show general symptoms of the disease. The invention also relates to a method for producing the inducers and to their use as drugs for the regulatory ... 06/28/07 - 20070148134 - Potent inhibition of influenza virus by specifically designed short interfering rna said sequences being inhibitory against influenza virus in animals including humans. The invention further includes one or more of said siRNA sequences in the form of an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a ... // - 3′ dTdTCCUAGAAUAAAGAAGCCUCUG 5′ - ... // - 5′ GGAUCUUAUUUCUUCGGAGACdTdT 3′ - ... // - 3′ dTdTACUUCCUAGAAUAAAGAAGCC 5′ - ... // - 5′ UGAAGGAUCUUAUUUCUUCGGdTdT 3′ - ... // - 3′ dTdTACUUCCUAGAAUAAAGAAG 5′ - ... // - 5′ UGAAGGAUCUUAUUUCUUCdTdT 3′ - ... 06/28/07 - 20070148133 - Potent inhibition of influenza virus by specifically designed short interfering rna said sequences being inhibitory against influenza virus in animals including humans. The invention further includes one or more of said siRNA sequences in the form of an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a ... // - 3′ dTdTCCUAGAAUAAAGAAGCCUCUG 5′ - ... // - 5′ GGAUCUUAUUUCUUCGGAGACdTdT 3′ - ... // - 3′ dTdTACUUCCUAGAAUAAAGAAGCC 5′ - ... // - 5′ UGAAGGAUCUUAUUUCUUCGGdTdT 3′ - ... // - 3′ dTdTACUUCCUAGAAUAAAGAAG 5′ - ... // - 5′ UGAAGGAUCUUAUUUCUUCdTdT 3′ - ... 06/28/07 - 20070148132 - Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system A vector and a method are provided for delivering a nucleic acid to a nervous system cell. The vector includes a first nucleic acid, a second nucleic acid, inverted terminal repeats of adeno-associated virus, and a tetracycline-off regulatable promoter system that includes a first promoter operably linked to the first ... 06/21/07 - 20070141030 - Targeted pre-mrna/mrna modification and gene regulation Methods for affecting mRNA expression or translation through the modification of pre-mRNA or mRNA transcripts are described. In one embodiment of the methods of the present invention, the branch point adenosine of a pre-mRNA transcript is 2′-O-methylated to block splicing and subsequent expression of the protein encoded by the transcript. ... 06/21/07 - 20070141029 - Methods of gene therapy for treating disorders of the ear by adminstering a vector encoding an antonal-associated factor The invention is directed to a method of changing the sensory perception of an animal. The method comprises administering an expression vector comprising a nucleic acid sequence encoding an atonal-associated factor, which is expressed to produce the atonal-associated factor resulting in generation of hair cells that allow perception of stimuli ... 06/21/07 - 20070141028 - Cancer gene therapeutic drug A cancer gene therapeutic drug of the present invention includes a carrier cell to be infected with an oncolytic virus, so as to make the oncolytic virus act on a tumor cell within a living body, wherein the carrier cell is selected from A549 cell, 293 cell, SW626 cell and ... 06/21/07 - 20070141027 - Non-lethal conditioning methods for conditioning a recipient for bone marrow transplantation Mixed chimerism induces donor-specific transplantation tolerance to organ allografts. Strategies to establish mixed chimerism using partial conditioning having significantly reduced the morbidity associated with conditioning. The donor hematopoietic cell lineage(s) responsible for the induction and subsequent maintenance of tolerance in partially conditioned recipients are not defined at present. As one ... 06/14/07 - 20070134206 - Targeting proteins to deliver therapeutic or diagnostic reagents The present invention is directed to compositions comprising an angiogenesis inhibitor coupled to a therapeutic or diagnostic agent. In a specific embodiment, the composition is a fusion gene or fusion gene product encoding the angiogenesis inhibitor coupled to a therapeutic or diagnostic agent. In a particular embodiment, the composition is ... 06/14/07 - 20070134205 - Gene delivery of detoxifying agent Gene delivery of a detoxifying agent is described. ... 06/14/07 - 20070134204 - Method for treating nerve injury and vector construct for the same A method is provided for treating a nerve injury, including steps of: transforming the nerve injury site with a gene coding for an acid fibroblast growth factor (aFEF); and allowing the gene to be expressed at the nerve injury site. Also provided is a vector for use in the method. ... 06/14/07 - 20070134203 - Compositions and methods for increasing packaging and yields of recombinant adenoviruses using multiple packaging signals A recombinant adenoviral vector which has multiple adenovirus packaging domains is provided. This vector has advantages over conventional adenoviral vectors in packaging plasmid vectors into adenoviral capsids. Methods of making and using this vector are described. ... 06/14/07 - 20070134202 - Cancer gene therapeutic drug A cancer gene therapeutic drug of the present invention comprises a combination of: a virus for immunological treatment to be administered for inducing a CTL reaction within a living body to administration of a carrier cell; and a carrier cell to be infected with an oncolytic virus before the administration ... 06/14/07 - 20070134201 - Archaeon expression system The present invention relates to a sulfolobus expression vector comprising: (a) sulfolobus origin of replication; (b) the genes encoding the structural proteins and the site-specific integrase of SSV1, SSV2 or pSSVx, operatively linked to expression control sequences and a packaging signal; (c) one or more selectable marker gene(s), operatively linked ... 06/14/07 - 20070134200 - Immunogenic composition and methods A method of inducing an antigen-specific immune response in a mammalian subject includes the steps of administering to the subject an effective amount of a first composition comprising a DNA plasmid comprising a DNA sequence encoding an antigen under the control of regulatory sequences directing expression thereof in a mammalian ... 06/07/07 - 20070128169 - Inhibition of gene expression by delivery of polynucleotides to animal cells in vivo Described is a process for intravascular delivery of a polynucleotide to an extravascular cell of a mammal to inhibit gene expression. A polynucleotide containing sequence that is similar to a sequence in the gene to be expressed is made and inserted into a vessel in the mammal. The polynucleotide is ... 06/07/07 - 20070128168 - Novel genes regulated in the developing human ventral mesencephalon A human embryonal stem cell, neural stem cell, neural precursor cell, neural cell or dopaminergic neuron is genetically modified to overexpress at least one of certain genes identified as regulated in the developing human ventral mesencephalon, and more particularly, up-regulated in the ventral tegmentum. The genes are associated with dopaminergic ... 06/07/07 - 20070128167 - Complexing agents for compositions containing inclusion complexes The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used ... 06/07/07 - 20070128166 - Adenoviral vectors having a protein ix deletion This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 06/07/07 - 20070128165 - Recombinase-based system for expression of foreign proteins using adenovirus vectors In the present invention, viruses, plasmids or both are constructed which contain viral DNA and lox sites positioned such that site-specific recombination between lox sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express the Cre recombinase. ... 06/07/07 - 20070128164 - Polypeptide The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use ... 06/07/07 - 20070128163 - Adeno-associated virus-mediated delivery of angiogenic factors The use of recombinant adeno-associated virus (rAAV) virions for delivery of genes encoding angiogenic factors to muscle tissue is disclosed. The invention describes such methods of delivery and also describes methods for treating an ischemic condition such as myocardial ischemia. The methods include direct delivery of rAAV virions to a ... 05/31/07 - 20070122385 - Replication competent viruses capable of silencing virus inhibitory factor expression Described is a replication-competent virus capable of replication and having lytic capacity in target cells. The virus comprises in the genome thereof, at least one DNA sequence coding for a silencing factor functional in reducing expression of a target gene in the target cells, operably linked to one or more ... 05/24/07 - 20070116673 - Method for activating t cell protein phosphatase and therapeutical methods based thereon This invention relates to methods for activation of T cell protein tyrosine phosphatase (TCPTP) and for inhibiting tyrosine kinase signalling in an individual. The invention concerns a method for preventing or treating a disease or disorder in an individual, wherein said disease or disorder is curable by inhibiting tyrosine kinase ... 05/24/07 - 20070116672 - Treatment of rheumatic diseases The present invention relates to the treatment of rheumatic diseases with a vaccinia virus complement control protein (VCP). ... 05/24/07 - 20070116671 - Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides The invention relates to immobilized or encapsulated enzyme and/or cells to lower bile acids and cholesterol. The invention also relates to methods of quantitatively measuring bile acids. The invention provides a composition for decreasing the amount of a target compound in the gastrointestinal tract of an animal, comprising: a) a ... 05/24/07 - 20070116670 - Use of the adenoviral e2 promoter The invention relates to a nucleic acid construct comprising an adenoviral E2 late promoter or a fragment thereof and a nucleic acid. The nucleic acid is selected from the group of transgenes, genes and nucleic acids which are respectively different from adenoviral nucleic acid controlled by an E2 late promoter. ... 05/17/07 - 20070110724 - Duplexed parvovirus vectors The present invention provides duplexed parvovirus vector genomes that are capable under appropriate conditions of forming a double-stranded molecule by intrastrand base-pairing. Also provided are duplexed parvovirus particles comprising the vector genome. Further disclosed are templates and methods for producing the duplexed vector genomes and duplexed parvovirus particles of the ... 05/17/07 - 20070110723 - Delivery of trefoil peptides The present invention relates to a microorganism, preferably a bacterial strain, preferably a non-pathogenic strain, preferably a non-invasive strain, preferably a food grade strain, preferably a gram-positive bacterial strain, delivering a trefoil peptide in vivo. Preferably said trefoil peptide is TFF1. The present invention further relates to a method for ... 05/17/07 - 20070110722 - Methods and compositions for the synthesis of rna and dna Methods for the production of duplexes and single-stranded RNA and/or DNA of a desired length and sequence based on a novel template design which incorporates 2 polymerase promoters, primers, and production sequences within a single molecule are provided. This Single-stranded Template molecule design allows high-efficiency, high-yield production of single or ... 05/17/07 - 20070110721 - Plasmid maintenance The invention relates to a system for stable maintenance of a plasmid, to host cells for use in this system and to methods of using the system to obtain a plasmid useful in medical applications. In particular, the invention provides transformed host cell containing: i) a chromosomal gene which inhibits ... 05/17/07 - 20070110720 - Vectors, mutant viruses and methods for generating mutant viruses A nucleic acid vector comprising first and second nucleotide sequences corresponding to nucleotide sequences flanking an insertion site in the genome of a selected herpes simplex virus strain; and a cassette located between said first and second nucleotide sequences comprising nucleic acid encoding: (a) one or a plurality of insertion ... 05/17/07 - 20070110719 - Novel use of adenoviruses and nucleic acids that code for said viruses The present invention is related to the use of a virus, preferably an adenovirus, for the manufacture of a medicament, whereby the virus is replication deficient in cells which do not have YB-1 in the nucleus, and the virus codes for an oncogene or oncogene product, in particular an oncogene ... 05/17/07 - 20070110718 - System for treating and preventing breast cancer The present invention is directed to a system for treating individuals at risk of or suffering from breast cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains in a foreign nucleic acid encoding at least one breast cancer antigen. ... 05/17/07 - 20070110717 - Dna vaccines against tumor growth and methods of use thereof A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carrier. In a preferred embodiment, the polynucleotide construct is operably incorporated ... 05/17/07 - 20070110716 - Relationship of a specific metabolite to insulin resistance Provided are methods and reagents for reducing ketone levels (for example, β-hydroxybutyrate) in skeletal muscle. Also provided are methods and reagents for treating insulin resistant states, such as diabetes. Further provided are screening methods for identifying compounds to reduce skeletal muscle ketone levels and/or to treat insulin resistance, for example, ... 05/10/07 - 20070104690 - Retroviral vectors Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent, from the system. The systems and resulting retrovirus vector ... 05/10/07 - 20070104689 - Compositions and methods for treating tumors presenting survivin antigens The present invention provides compositions and methods that elicit an immune response against diseased cells. In particular, the present invention provides compositions and methods for the presentation of a peptide related to survivin on antigen-presenting cells. Presentation of the peptide leads to an immune response in a mammal against cells ... 05/10/07 - 20070104688 - Small interfering rna mediated transcriptional gene silencing in mammalian cells The present invention relates to transcriptional gene silencing (TGS) in mammalian, including human, cells that is mediated by small interfering RNA (siRNA) molecules. The present invention also relates to a method for directing histone and/or DNA methylation in mammalian, including human, cells. It has been found that siRNAs can be ... 05/10/07 - 20070104687 - Aav vectors for in vivo gene therapy of rheumatoid arthritis The present invention relates to the field of adeno-associated virus (AAV) based gene therapy, in particular in vivo gene therapy, of rheumatoid arthritis (RA). The invention provides recombinant AAV virions being highly efficient in delivering genes encoding therapeutic proteins to the arthritic joints, and method for using such virions in ... 05/10/07 - 20070104686 - Vaccines, immunotherapeutics and methods for using the same Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes an immunomodulator protein selected from the group consisting of: Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, IkB, Inactive ... 05/10/07 - 20070104685 - Synthetic gene encoding human carcinoembryonic antigen and uses thereof Synthetic polynucleotides encoding human carcinoembryonic antigen (CEA) are provided, the synthetic polynucleotides being codon-optimized for expression in a human cellular environment. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product ... 05/10/07 - 20070104684 - Ocular gene therapy Methods are provided for the treatment of choroidal neovascularization by increasing, in an individual afflicted with choroidal neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to a choroidal neovascularization inhibiting effective amount, where the endostatin protein has anti-choroidal neovascularization activity in vivo. ... 05/03/07 - 20070098692 - Materials and methods for treating ocular-related disorders The present invention is directed to a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder, e.g., ocular neovascularization or age-related macular degeneration. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and ... 05/03/07 - 20070098691 - Prostate specific antigen oligo-epitope peptide The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific ... 05/03/07 - 20070098690 - Truncated cmv promoters and vectors containing same The present invention relates to nucleic acid molecules comprising certain truncated forms of the human cytomegalovirus (CMV) immediate-early enhancer-promoter, either alone or operably linked to transgenes of interest, including those encoding partially-deleted CFTR proteins. This invention further relates to vectors comprising these nucleic acid molecules and host cells transformed by ... 05/03/07 - 20070098689 - Mutant viruses An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a nitroreductase (NTR) is disclosed. Disclosed herpes simplex viruses are indicated to be useful in the treatment of cancer which may involve gene directed enzyme prodrug therapy. ... 04/26/07 - 20070092490 - High efficiency sin vector The present application discloses viral vector that includes the following elements: (1) a promoter in U3 region of MSV 5′LTR; (2) repeating unit of MSV 5′LTR; (3) U5 region of MSV 5′LTR; (4) packaging signal; (5) a promoter; (6) internal ribosome entry site (IRES); (7) defective MLV 3′ LTR; (8) ... 04/26/07 - 20070092489 - Use of receptor sequences for immobilizing gene vectors on surfaces The present invention relates to compositions and methods of immobilizing a viral vector to an implantable medical device, for example a vascular stent. Specifically, a composition for delivery of a therapeutic agent is provided which includes: a gene transfer vector, a surface and a modified protein, wherein the gene transfer ... 04/19/07 - 20070086985 - Vectors for tissue-specific replication The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per ... 04/19/07 - 20070086984 - Viruses for the treatment of cellular proliferative disorders Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, ... 04/19/07 - 20070086983 - Endothelium-targeting nanoparticle for reversing endothelial dysfunction The present invention includes delivery of isolated and purified nucleic acids that encode GTPCH proteins in nanoparticles for the treatment of endothelial cells damaged by diabetes, smoking, dyslipidemia, hypertension, and cardiovascular disease. The nanoparticles contain a nucleic acid sequence, polymer and a targeting ligand. The targeting ligand facilitates the selective ... 04/19/07 - 20070086982 - Gene therapy for regulating smooth muscle tone The present invention is directed towards a method of regulating smooth muscle tone, comprising the introduction, into smooth muscle cells of a subject, of a DNA sequence encoding a protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth ... 04/19/07 - 20070086981 - Delivery peptides, their constructs with active agents and use The present invention refers to delivery proteins, protein-cargo complexes, methods, and means for the enhanced delivery or transport of drugs, biologically active agents or other compounds as cargo or cargo molecules onto, into, or across biological membranes or tissues forming a biological barrier. ... 04/12/07 - 20070081978 - Adeno-associated virus-mediated survivin mutants and methods related thereto This invention provides two novel vectors, a vector comprising a rAAV-type 2 plasmid encoding mutant survivin (Cys84Ala), and a vector comprising a rAAV-type 2 plasmid encoding eGFP. This invention also provides compositions comprising the above vectors. This invention provides a method for inducing apoptosis in a cell comprising introducing into ... 04/12/07 - 20070081977 - Device for transdermal administration of active substances A device for transdermal administration of active substances, comprising a backing layer and an active substance-containing reservoir connected to the backing layer. The skin-facing contact surface of the device has a plurality of microprotrusions which are suitable for penetrating the skin and which are equipped with structures that make extracting ... 04/05/07 - 20070077234 - Regulation of t cell-mediated immunity by tryptophan A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in ... 04/05/07 - 20070077233 - Inhibition of pathological angiogenesis in vivo The present invention is directed to the inhibition of pathological angiogenesis in different tissues such as cancer, tumor, retinal or synovial tissue. It has been shown that over expression of RB2/p130 modulates the angiogenetic balance. It has been further shown that induction of RB2/p130 expression using a tetracycline-regulated gene expression ... 04/05/07 - 20070077232 - Conditioned cell culture medium compositions and methods of use Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal ... 04/05/07 - 20070077231 - Immune effector cells pre-infected with oncolytic virus Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect ... 04/05/07 - 20070077230 - Method for the pre-conditioning/fixation and treatment of diseases with heat activation/release with thermo-activated drugs and gene products A method of treating cancer by introducing heat into cancerous tissue and delivering a liposome containing an active agent or a thermo-activated drug, gene or virus to said tissue. The heat delivered is sufficient to release the active agent or activate the thermo-activated drug, gene or virus. The cancer can ... 04/05/07 - 20070077229 - Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a KLH1 haemocyanin, a haemocyanin domain or a fragment thereof with the immunological properties of at least one domain of haemocyanin, and comprises at least one intron sequence, as well ... 04/05/07 - 20070077228 - Method of treating or retarding the development of blindness A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the ... 04/05/07 - 20070077227 - Nucleic acid binding proteins The invention provides a method for designing a nucleic acid binding protein of the Cys2-His2 zinc finger class capable of binding to a nucleic acid quadruplet in a target nucleic acid sequence, wherein binding to base 4 of the quadruplet by an alpha-helical zinc finger nucleic acid binding motif in ... 04/05/07 - 20070077226 - Gutless adenovirus vector and the construction method thereof The present invention disclosed a kind of gutless adenovirus vector and the construction method thereof. Two structural independent but functional related cassettes, the trans-activator (TA) and anti-tumor cassette, are both carried by the gutless vector. hTERT promoter restricts the expression of TA only in tumor cells, and RU486, associated with ... 03/29/07 - 20070071726 - Recombinant viral-based malaria vaccines The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are ... 03/29/07 - 20070071725 - Nitric oxide synthase gene transfer This invention relates to to gene transfer, specifically, provided herein are methods, vectors and compositions for the transfer of nNOS gene affecting overexpression of nNOS in sympathetic and parasympathetic nervous system and its subsequent use in the treatment of related pathologies. ... 03/29/07 - 20070071724 - Methods for increasing learning and memory in amyloid-beta-related neurodegenerative disorders by increasing uch-l1 activity and methods for identifying enhancers of uch-l1 activity The invention is directed to methods for increasing learning and memory in a subject with a neuropathological condition, specifically a condition related to elevated beta-amyloid deposition, the method comprising administering to the subject an effective amount of a compound capable of increasing the activity of Uch-L1. The invention is also ... 03/29/07 - 20070071723 - In vivo enhancement of immune system recognition of neoplasms following treatment with an oncolytic virus or gene therapy vector This invention provides novel methods of treating or alleviating neoplasms and enhancing the efficacy of oncolytic viruses by administering an oncolytic virus to a mammal suffering from a neoplasm and subsequently administering an immunostimulant. The invention also provides methods of increasing immunorecognition of neoplastic cells. ... 03/29/07 - 20070071722 - Nucleotide vaccine composition The present invention refers to a novel combination of nucleotide and cellular vaccine composition and pharmaceutical composition and use thereof for treating and/or preventing diseases, including infectious diseases, cancer, autoimmune diseases, allergy, diabetes and blood disorders. The vaccine composition comprises a nucleotide sequence encoding an antigenic molecule and gene-modified antigen-presenting ... 03/22/07 - 20070065412 - Production of recombinant aav using adenovirus comprising aav rep/cap genes This invention relates to novel adenoviruses useful in the production of high titers of recombinant adeno-associated virus (rAAV) comprising a foreign DNA inert and methods of making these adenoviruses. The adenovirus comprises the AAV rep gene in which the p5 promoter of rep is replaced by a minimal promoter or ... 03/22/07 - 20070065411 - Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses The present invention concerns methods and compositions for the treatment of cancer and cancer cells using intravascular administration of a vaccinia virus. In some embodiments, methods and compositions involve a replicative vaccinia virus that encodes GM-CSF. ... 03/22/07 - 20070065410 - Peptides binding the phosphatase 2a protein and polynucleotides encoding same The invention relates to novel synthetic or natural E4orf4 or Bcl-2 peptides particularly useful in antitumoral, antiviral and antiparasitic treatments, said peptides being less than 30 amino acids long and binding in vitro to a phosphatase 2A protein holoenzyme or one of its subunits. The invention also relates to polynucleotides ... 03/22/07 - 20070065409 - Use of pleiotrophin in the diagnosis, treatment and prevention of disease Described herein are methods for transdifferentiating monocytes/macrophages into endothelial cells, based on the inventors' identification of pleiotrophin (“PTN”) as the gene responsible for this transdifferentiation. Further described are therapeutic methodologies for the promotion or inhibition of neovasculanization based on modulation of PTN. ... 03/22/07 - 20070065408 - Modified polypeptides for targeting cell-entry of the adenoviruses of subtype b This invention relates to modified polypeptides comprising two functional components: first, a polypeptide derived from the extracellular region of CD46 as a specific binding site for adenoviruses of the subgroup B, and second, a component capable of binding to a cell surface molecule. Such modified polypeptides are able to direct ... 03/15/07 - 20070059291 - Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (lcmv) The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy. ... 03/15/07 - 20070059290 - Transcriptional regulation of target genes The present invention describes a method of identifying inducible genetic regulatory sequences that can control the transcription of specific gene transcripts. Methods of using inducible genetic regulatory sequences are also discussed. In particular, the genetic regulatory sequences of the present invention can modulate the transcription of a nucleic acid transcript ... 03/15/07 - 20070059289 - Methods of improving cardiac function and attenuating and/or preventing cardiac remodeling with hsp20 Methods of improving cardiac function and/or methods for attenuating and/or prevention cardiac remodeling in an individual's heart comprising administering to an individual an effective amount of Heat-Shock Protein Hsp20 or an agent that increase the levels of and/or the activity of Hsp20 are provided. ... 03/15/07 - 20070059288 - Treatment for heart disease The present invention provides a system for treating heart disease using a combination of pro-angiogenesis therapy and cellular cardiomyoplasty. The system is particularly useful in treating patients with damaged myocardium due coronary artery disease, myocardial infarction, congestive heart failure, and ischemia. A pro-angiogenic factor (e.g., VEGF) or a means of ... 03/15/07 - 20070059287 - Modified tert promoter with enhanced tumor-specificity and strength and recombinant vector comprising the same The present invention relates to a transcriptional regulatory sequence with enhanced tumor-specificity and strength and a recombinant vector comprising the transcriptional regulatory sequence. More particularly, the present invention relates to a transcriptional regulatory sequence comprising a human telomere reverse transcriptase (hTERT) promoter linked to a nucleotide sequence that comprises one ... 03/15/07 - 20070059286 - Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity The present invention describes DNA vaccines that encode for and direct the coincident expression of an antigen and an ADP-ribosyltransferase toxin that is devoid of ADPribosyltransferase activity and methods for vaccinating animals with the same. The DNA vaccines are useful for vaccinating against viral, bacterial and parasitic pathogens. ... 03/08/07 - 20070053880 - Growth differentiation factor-16 Growth differentiation factor-16 (GDF-16) is disclosed along with its polynucleotide sequence and amino acid sequence Also disclosed are diganostic and therapeutic methods of using the GDF-16 polypeptide and polynucleotide sequences. ... 03/08/07 - 20070053879 - Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator Disclosed are full length isolated DNAs encoding cystic fibrosis transmembrane conductance regulator (CFTR) protein and a variety of mutants thereof. Also disclosed are antibodies specific for various CFTR domains and methods for their production. Expression of CFTR from cells transformed with these CFTR genes or cDNAs demonstrate surprising CFTR intracellular ... 03/01/07 - 20070048287 - Molecular antigen array The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ... 03/01/07 - 20070048286 - Method of treating dopaminergic and gaba-nergic disorders It is shown here that hedgehog proteins possess novel activities beyond phenotype specification. Using cultures derived from the embryonic day 14.5 (E14.5) rat ventral mesencephalon, we show that hedgehog is also trophic for dopaminergic neurons. Interestingly, hedgehog not only promotes dopaminergic neuron survival, but also promotes the survival of midbrain ... 03/01/07 - 20070048285 - Self-inactivating retroviral vector The invention relates to retroviral vectors, especially to self-inactivating (SIN) gammaretroviral or lentiviral vectors, suitable for producing viral particles at high titers, which can be used for efficient gene transfer into mammalian cells, organs or organisms, e.g. for gene therapy. More specifically, the present invention provides modified 5′-promoter elements in ... 03/01/07 - 20070048284 - Cardiac arrhythmia treatment methods Disclosed are methods of preventing or treating cardiac arrhythmia. In one embodiment, the methods include administering to an amount of at least one polynucleotide that modulates an electrical property of the heart. The methods have a wide variety of important uses including treating cardiac arrhythmia. ... 03/01/07 - 20070048283 - Methods of inducing an immune response Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene ... 02/22/07 - 20070041947 - Use of a lentiviral vector in the treatment of pain Provided is a method for treating and/or preventing pain, in which a vector system is administered such that an EOI is delivered to a DRG of the subject. Also provided is a method for delivering an EOI to the spinal cord using such a vector system. Further provided is a ... 02/22/07 - 20070041946 - Serotype of adenovirus and uses thereof Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins ... 02/22/07 - 20070041945 - Novel method for down-regulation of amyloid A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal ... 02/22/07 - 20070041944 - Treating tumors by enh dislocation of id proteins The invention provides methods for the therapy of cancer that are directed towards preventing or inhibiting Id function. The present methods are based on contacting neoplastic or tumor cells with agents that can translocate an Id protein to the cytoplasm and/or sequester an Id protein in the cytoplasm, thereby preventing ... 02/22/07 - 20070041943 - Expression of virus entry inhibitors and recombinant aav thereof The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals. ... 02/22/07 - 20070041942 - Use of calcium binding proteins to improve cardiac contractile function Methods useful in the regulation of myocardial contraction are disclosed. The methods are useful in the regulation of heart function. The invention reveals that sorcin overexpression enhances cardiac contractile performance and establishes the concept of sorcin as a regulator of myocardial contractility. The invention also provides screening assays that allow ... 02/22/07 - 20070041941 - Nucleic acid sequences encoding and compositions comrpising ige signal peptide and/or il-15 and methods for using the same Fusion proteins and nucleic acid molecules encoding fusion proteins are disclosed. Fusion proteins comprising non-IL-15 signal peptide linked to IL-15 protein sequences and fusion proteins comprising an IgE signal peptide linked to non-IgE protein sequences are disclosed. Vectors comprising such nucleic acid molecules; and to host cells comprising such vectors ... 02/15/07 - 20070036764 - Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr Novel methods and compositions for selective killing of cells by activation of PKR are disclosed. In a preferred embodiment, a method is provided for causing cell death in a targeted population of cells that includes the steps of: selecting a nucleotide sequence at a single genetic locus in the targeted ... 02/15/07 - 20070036763 - Interleukin-17 receptor homologue Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.” ... 02/15/07 - 20070036762 - Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer A novel gene (designated 85P1B3) and its encoded protein are described. While 85P1B3 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 85P1B3 provides a diagnostic and/or therapeutic target for cancers. The 85P1B3 gene or fragment thereof, ... 02/15/07 - 20070036761 - Lentiviral apoe2 gene therapy The present invention is a method for inhibiting or reducing disease progression in subjects suffering from conditions or diseases related to the Aβ peptide, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like. The method comprises admininstering an apoE2 lentiviral vector to the subject. ... 02/15/07 - 20070036760 - Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided. ... 02/15/07 - 20070036759 - Method of preparing a proliferation-regulated recombinant adenoviral vector efficiently and kit for preparing the same Provided is a method of preparing a proliferation-regulated recombinant adenoviral vector effectively, comprising preparing a proliferation-regulated vector plasmid by preparing a restriction enzyme-recognizing sequence in a vector plasmid having a proliferation-regulating unit and having an E1A region, a protein-coding region in a E1B region, a poly(A) signal sequence, and a ... 02/15/07 - 20070036758 - Mutants of vaccinia virus as oncolytic agents The present invention relates to mutant oncolytic vaccinia viruses and their use for selective destruction of cancer cells. The mutant vaccinia viruses of the invention include those having a reduced ability to inhibit the antiviral dsR-NA dependent protein kinase (PKR) and increased sensitivity to interferon. Such mutants include, for example, ... 02/15/07 - 20070036757 - Aav vector for gene therapy Described are recombinant AAV vectors characterized in that they carry capsid protein modification(s) resulting in a reduced or eliminated heparin binding function. The AAV vectors of the present invention are particularly suitable for gene therapy by systemic application, since (a) transduction of the liver is eliminated or at least drastically ... 02/15/07 - 20070036756 - Method for treating ischemic diseases The present invention provides methods for treating ischemic diseases, which comprise the step of administering angiopoietin-1 (Ang1) or an Ang1-encoding vector. The present invention also provides ischemic disease treatment kits which comprise Ang1. Ang1-expressing vectors were prepared, and each was administered alone intramyocardially to rats in the acute phase of ... 02/08/07 - 20070031383 - Recombinant herpes simplex virus useful for treating neoplastic disease Recombinant herpes simplex viruses comprising DNA encoding cytokines and methods for treating neoplastic diseases using the inventive recombinant viruses are disclosed. ... 02/08/07 - 20070031382 - Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same A method for introducing and expressing genes in animal cells is disclosed comprising infecting the animal cells with live invasive bacteria, wherein the bacteria contain a eukaryotic expression cassette encoding the gene. The gene may encode, e.g., a vaccine antigen, a therapeutic agent, an immunoregulatory agent or an anti-sense RNA ... 02/08/07 - 20070031381 - Recombinant adenoviral vector and method of use This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 02/08/07 - 20070031380 - Integration-site directed vector systems Some aspects of the application describe materials and methods for making a molecular tether. A molecular tether, in certain embodiments, includes a target-DNA-binding domain having a specific binding affinity for a target-DNA segment in a host chromosome, a carrier-binding domain that specifically binds to a DNA segment on a carrier, ... 02/08/07 - 20070031379 - Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same The present invention relates to an anticancer or an anti-metastatic agent for gene therapy, more precisely, an anticancer or an anti-metastatic agent for gene therapy containing a gene carrier or cells harboring human apolipoprotein (a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) gene as an effective ingredient, and a treatment method ... 02/08/07 - 20070031378 - Minicircle vector production A plasmid is provided comprising comprising the following functional units: a prokaryotic origin of replication, a marker sequence, two specific recombinase recognition sequences and a multiple cloning site, whereby it comprises a gene coding for a sequence specific recombinase, whereby the units are arranged on the plasmid in such a ... 02/01/07 - 20070025971 - Substances causing differentiation A DNA construct is described which contains a fusion gene under the control of a promoter. The fusion gene comprises at least one resistance gene and at least one reporter gene and is slightly toxic to a host cell transfected with that DNA construct. That DNA construct can be encoded ... 02/01/07 - 20070025970 - Vector system The present invention relates to retroviral vector genomes and to vector systems comprising such genomes. In particular the present invention relates to a retroviral vector genome comprising two or more NOIs operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs ... 02/01/07 - 20070025969 - Rnai expression constructs The present invention provides compositions and methods suitable for expressing 1-x RNAi agents against a gene or genes in cells, tissues or organs of interest in vitro and in vivo so as to treat diseases or disorders. ... 02/01/07 - 20070025968 - Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes The present invention relates to the field of molecular biology and immunology. In particular it relates to vaccines and methods for providing vaccines which elicit immune responses when administered to a mammal, in particular a human. The preferred elicited immune response is a T cell response, elicited by peptide T ... 02/01/07 - 20070025967 - Zap protein and related compositions and methods This invention provides an isolated ZAP protein and methods and articles of manufacture for increasing resistance to a virus in a subject or mammalian cell. The instant methods and articles are based on the use the ZAP protein to increase such resistance to a virus. ... 01/25/07 - 20070020239 - Heximi as a suppressor of hiv replication and cardiac hypertrophy Cellular transcription is modulated by increasing or decreasing the amount of active HEXIM1 in the cell. The methods are applied to the treatment of HIV infection and cardiac hypertrophy. Assays using reconstituted 7SK:P-TEFb snRNP screen for agents that modulate HEXIM1-P-TEFb binding. ... 01/25/07 - 20070020238 - Method of targeted gene delivery using viral vectors Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic ... 01/25/07 - 20070020237 - Glucose inducible insulin expression and methods of treating diabetes The invention provides an isolated tissue specific glucose responsive promoter having a polymerase binding domain 3′ to at least one tripartite transcription factor binding cis element having a hepatocyte nuclear factor-1 (HNF-1) element, a CAAT/enhancer binding protein (C/EBP) response element and a glucose-response element (GRE). The promoter can include a ... 01/25/07 - 20070020236 - Defective sindbis viral vectors Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for ... 01/18/07 - 20070014769 - Adenovirus vectors comprising meganuclease-type endonucleases, and related systems The present invention relates to methods for efficient and reliable construction of adenovirus vectors which contain and express foreign DNA and are useful for gene transfer into mammalian cells, for vaccines and for gene therapy. The invention provides for the growth and purification of adenovirus vectors (helper dependent vectors or ... 01/18/07 - 20070014768 - Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition ... 01/18/07 - 20070014767 - Tgfbeta1-inhibitor peptides Antagonistic synthetic peptides, obtained from TGFβ1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment ... 01/18/07 - 20070014766 - Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof The present invention provides methods for promoting generation of heart tissue, and for treating and preventing heurt tissue degeneration. Additionally, the present invention provides a therapeutic composition comprising a cyclin-associated agent, and a kit comprising the composition. The present invention further provides a heart tissue tell, a sidepopulation progenitor tell, ... 01/11/07 - 20070009488 - Feline granulocyte macrophage colony stimulating factor nucleic acid molecules The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins; to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine ... 01/11/07 - 20070009487 - Minimal promoters and uses thereof Minimal promoter sequences are described. Reagents including a nucleic acid molecule which contains these minimal promoter sequences are also described. Methods for constructing these reagents, and methods for using these reagents are also described. ... 01/11/07 - 20070009486 - Adenoviral vectors having a protein ix deletion This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 01/11/07 - 20070009485 - Nucleic acid delivery The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods ... 01/11/07 - 20070009484 - Compositions and methods involving mda-7 for the treatment of cancer The present invention concerns methods and compositions involving MDA-7 protein or an MDA-7-encoding nucleic acid in combination with either 1) a COX-2 selective inhibitor, such as celecoxib, 2) an Hsp90 inhibitor, such as geldanamycin, or a geldanamycin derivative or analog, 3) a vitamin E compound, for the treatment of cancer, ... 01/11/07 - 20070009483 - Compositions and methods for the therapeutic treatment of diabetes The invention provides a vector having a nucleic acid operably linking a promoter, an intron, a secretory leader sequence encoding nucleic acid, a human betacellulin (BTC) encoding nucleic acid, or functional fragment thereof, and a polyadenylation signal sequence, wherein expression of BTC produces a secreted, mature BTC. Also provided is ... 01/11/07 - 20070009482 - Immunomodulatory oligonucleotides Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides ... 01/11/07 - 20070009481 - Use of fak-related non-kinase in the manufacture of a medicament for the inhibition of stenosis and restenosis The present invention is related to the use of an adeno-associated virus, whereby the adeno-associated virus comprises a) FRNK or a derivative thereof, or b) a nucleic acid encoding FRNK or a derivative thereof, or of a nucleic acid coding for an adeno-associated virus, whereby the nucleic acid comprises a ... 01/04/07 - 20070003524 - Targeted retrograde gene delivery to motor neurons Methods are disclosed for delivering a heterologous gene to a cell body of a neuron by contacting a muscle tissue innervated by the neuron with a viral vector comprising a heterologous gene, wherein the viral vector enters said neuron and is retrogradely moved to the cell body. Additionally, methods for ... 01/04/07 - 20070003523 - Compositions and methods for sirna inhibition of angiogenesis RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types ... 01/04/07 - 20070003522 - Methods and compositions for improved retroviral gene and drug delivery The present invention provides recombinant viral particles for gene therapy and liposome compositions for drug delivery comprising an env protein of MMTV. The invention also provides retroviral or lentiviral env proteins comprising a mutation in a receptor-binding motif. The invention also provides nucleic acids, proteins, and compositions comprising the recombinant ... 01/04/07 - 20070003521 - Expression vectors containing hybrid ubiquitin promoters Sustained transgene expression will be required for the vast majority of genetic diseases being considered for gene therapy. The initially high levels of expression attained with plasmid DNA (pDNA) vectors containing viral promoters, such as that from cytomegalovirus (CMV), decline precipitously to near background levels within 2 to 3 weeks. ... 01/04/07 - 20070003520 - Mutant viruses An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of ... 01/04/07 - 20070003519 - Targets for tumor growth inhibition The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that ... 01/04/07 - 20070003518 - Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases Disclosed are recombinant adeno-associated viral (rAAV) vector compositions that are expressed in selected mammalian cells, such as pancreatic islets cells, and that encode one or more mammalian serpin or cytokine polypeptides having therapeutic efficacy in the amelioration, treatment and/or prevention of interleukin deficiencies, such as for example diabetes, and related ... 12/28/06 - 20060292123 - Adeno-associated virus-mediated delivery of gdnf to skeletal muscles Compositions and methods for delivering GDNF to skeletal muscles to result in a therapeutic effect are disclosed. The compositions and methods use adeno-associated virus (AAV)-based gene delivery systems. The methods are useful for treating motoneuron diseases, such as amyotrophic lateral sclerosis (ALS). ... 12/28/06 - 20060292122 - Adenoviral vectors for treating diseases Adenoviral vectors, including mutant adenoviruses, that have restriction sites in the E3 region, that facilitate its partial or total deletion, or select genes contained therein, and optionally compositions and methods for substituting heterologous gene(s) in the partially or totally deleted E3 region(s), which heterologous gene(s) being operably linked to endogenous ... 12/28/06 - 20060292121 - Retroviral vectors including modified envelope escort protein A retroviral vector comprising a first retroviral envelope protein and at least one modified retroviral envelope protein, wherein said first retroviral envelope protein includes a surface protein comprising (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion, and said modified retroviral envelope protein, prior ... 12/28/06 - 20060292120 - Compositions and methods for sirna inhibition of angiogenesis RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types ... 12/28/06 - 20060292119 - Modulation of negative immune regulators and applications for immunotherapy The invention includes compositions and methods for enhancing immunopotency of an immune cell by way of inhibiting a negative immune regulator in the cell. The present invention provides vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The present invention also provides a mechanism ... 12/28/06 - 20060292118 - Hollow nanoparticles of protein and drug using the same The subject invention is hollow nanoparticles that comprise particle-forming first proteins (e.g. hepatitis B virus surface-antigen protein), containing a bio-recognizing molecule for recognizing a specific cell, wherein at least one of the first proteins interacts with a second protein (e.g. hepatitis B virus core-antigen protein) forming a capsid structure. With ... 12/28/06 - 20060292117 - Improved raav vectors Disclosed are methods for the use of therapeutic polypeptide-encoding polynucleotides in the creation of transformed host cells and transgenic animals. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions that specifically target mammalian cells, such as pancreatic islets cells, that express low-density lipoprotein receptors on their cell surface. ... 12/21/06 - 20060286075 - Method and compositions for treating hepatocellular cancer A method for preventing or for treating cancer in a mammal, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface. The method comprises creating an immune response in the mammal to at least part of the amino acid sequence of an ... 12/21/06 - 20060286074 - Methods for immunotherapy of cancer Provided are methods of generating an immune response to an antigen specifically associated with tumor vascular endothelial cells (TVECA). The method comprises administering to an individual an expression vector encoding the TVECA. The vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing a TVECA and ... 12/21/06 - 20060286073 - Compositions and methods for sirna inhibition of angiogenesis RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involved angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types ... 12/21/06 - 20060286072 - techniques and compositions for treating cardiovascular disease by in vivo gene delivery Methods are provided for treating patients with cardiovascular disease, including heart disease and peripheral vascular disease. The preferred methods of the present invention involve in vivo delivery of genes, encoding angiogenic proteins or peptides, to the myocardium or to peripheral ischemic tissue, by introduction of a vector containing the gene ... 12/21/06 - 20060286071 - Therapeutic pastes for medical device coating This invention provides a high-solids therapeutic composition for coating a medical device comprising: (a) a first material which is a hydrophilic therapeutic agent; and (b) a second material which includes a hydrophobic polymer and an emulsifying surfactant, wherein the composition is in a singular stable phase. Also provided is a ... 12/14/06 - 20060280725 - Compositions and methods of treating and diagnosing hepatoma Disclosed are pharmaceutical compositions and methods of treating hepatoma by administering to patients or other populations of cells agents that selectively inhibit the uptake of glutamine by hepatocarcinoma cells, causing the concomitant apoptosis of hepatocarcinoma cells. Preferred agents target the amino acid transporter B0 (ATB0) protein for inhibition. Disclosed are ... 12/14/06 - 20060280724 - Identification of ligands that enable endocytosis, using in vivo manipulation of neuronal fibers In vivo screening is used to identify and isolate ligands that drive endocytosis (internalisation) of molecules into animal cells. These ligands can transport passenger molecules (drug or diagnostic compounds, genetic vectors, etc.) into targeted classes of cells. A population of candidate ligands, such as a phage display or combinatorial library, ... 12/07/06 - 20060275267 - Nucleic acids encoding inactive variants of human telomerase The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. Catalytically inactive variants comprising deletions or other mutations are provided. ... 12/07/06 - 20060275266 - Tripeptide of fcyriia The present invention relates, in general, to phagocytosis and phagolysosomal fusion and, in particular, to a tripeptide of FcγRIIA that mediates trafficking of targets phagocytosed via FcγRIIA to the lysosomal compartment. ... 12/07/06 - 20060275265 - Potent inhibition of influenza virus by specifically designed short interfering rna said sequences being inhibitory against influenza virus in animals including humans. The invention further includes one or more of said siRNA sequences in the form of an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a ... // - 3′ dTdTCCUAGAAUAAAGAAGCCUCUG 5′ - ... // - 5′ GGAUCUUAUUUCUUCGGAGACdTdT 3′ - ... // - 3′ dTdTACUUCCUAGAAUAAAGAAGCC 5′ - ... // - 5′ UGAAGGAUCUUAUUUCUUCGGdTdT 3′ - ... // - 3′ dTdTACUUCCUAGAAUAAAGAAG 5′ - ... // - 5′ UGAAGGAUCUUAUUUCUUCdTdT 3′ - ... 12/07/06 - 20060275264 - Novel glutamic acid decarboxylase (gad) chimera and methods of use The invention relates to a novel Glutamic Acid Decarboxylase (GAD). More specifically, novel DNA and protein sequences relating to GAD. Additionally, the invention discloses a novel composition and related methods for treating neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, epilepsy, and the like, using viral and non-viral delivery systems ... 12/07/06 - 20060275263 - Cell proliferation inhibitory proteins and polynucleotides, antisense polynucleotides to the polynucleotides, cell proliferation inhibitors using the foregoing, cancer diagnostic agents, cancer therapeutic agents and compositions for gene therapy The genes the expression of which is reduced or disappeared in immortal cells including cancer cells are isolated, their DNA sequences are determined, the genes are expressed to produce cell proliferation inhibitory proteins, and the genes and the proteins are utilized as agents for diagnosis or treatment, including the genetic ... 12/07/06 - 20060275262 - Conditionally replicating viruses and methods for cancer virotherapy The present invention provides for methods and compositions for translation of a viral vector both in vitro and in vivo. Specifically, the present invention pertains to a translational control element placed in a vector to cause a selective translation of a viral vector. In one embodiment, the present invention provides ... 12/07/06 - 20060275261 - Adenoviral vectors having a protein ix deletion This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 11/30/06 - 20060269522 - Sequence of natural or synthetic retroelements enabling nucleotide sequence insertion into a eukaryotic cell A retroviral vector that eliminates cis-acting retroviral elements, which are not useful to and may cause problems for, an integrated provirus utilizes a recombination system, such as the bacteriophage P1 cre-lox recombination system. A gene of interest and a loxP site are inserted into a long terminal repeat, which is ... 11/30/06 - 20060269521 - Avoidance of undesirable replication intermediates in plasmid propagation Disclosed herein are improved plasmid shuttle vectors, vaccines based on them, and methods related to their construction and use. Particular arrangements of functional elements of such plasmids, namely origins of replication and eukaryotic transcription/translation control elements, which give rise to generally undesirable side-products upon propagation of the plasmids in bacterial ... 11/30/06 - 20060269520 - Xiap therapy The invention features methods, compositions and kits for the treatment of degenerative disorders. ... 11/30/06 - 20060269519 - Modulation of cytokine signaling regulators and applications for immunotherapy The present invention relates to regulation of antigen presentation by cytokine signaling regulators in antigen presenting cells, such as dendritic cells. The invention provides methods of modulating antigen presentation through modulation of cytokine signaling regulators, such as SOCS (SOCS1-7, CIS), SHP (SHP-1 and SHP-2) or PIAS (PIAS1, PIAS3, PIASx and ... 11/30/06 - 20060269518 - Small interference rna gene therapy Gene expression is inhibited in a cell by introducing into the cell a lentiviral vector encoding a siRNA specific for the gene. Lentiviral vectors encoding siRNA specific for a cancer-associated gene inhibited expression of the gene and caused cell death after being introduced into cancer cells. Viral replication in HIV-infected ... 11/23/06 - 20060263334 - Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 |